Source scope / renal recommendation differencesNew v7.4
Trizivir - product and source limitations
Use individually selected components if renal adjustment is necessary. Verify all active ingredients.
What to reconcileVerify the current prescribing information for this presentation.
2 source identities and dates
Trizivir - labeled renal guidanceDailyMed / product prescribing information | Source revision: DailyMed SPL version 2, posted Apr 28, 2014
Abacavir sulfate, lamivudine, and zidovudine (Trizivir), oral tablet
Read this stored source Trizivir - selected RX renal passageGlobalRPh RX List / product-label mirror | Source revision: Mirror revision not established in the reviewed passage.
Abacavir sulfate, lamivudine, and zidovudine (Trizivir), oral tablet
Read this stored source Selected renal passages reviewed; independent clinician adjudication pending. Added: v7.4.
Source scope / renal recommendation differencesNew v7.4
Triumeq - product and source limitations
Select the correct adult or pediatric presentation. Monitor for lamivudine toxicity at sustained CrCl 30-49 mL/min.
What to reconcileApply only to the stated formulation, indication and renal population.
2 source identities and dates
Triumeq - labeled renal guidanceDailyMed / product prescribing information | Source revision: DailyMed SPL version 30, posted Jan 26, 2026
Abacavir/dolutegravir/lamivudine (Triumeq), fixed-dose oral tablet
Read this stored source Triumeq - selected RX renal passageGlobalRPh RX List / product-label mirror | Source revision: Mirror revision not established in the reviewed passage.
Abacavir/dolutegravir/lamivudine (Triumeq), fixed-dose oral tablet
Read this stored source Selected renal passages reviewed; independent clinician adjudication pending. Added: v7.4.
label version or jurisdiction
International <50 threshold versus NIH U.S.-focused <30 position
The KIVEXA source advises against the fixed product below CrCl 50. NIH distinguishes U.S.-focused ABC/3TC guidance below 30 and qualified panel-member continuation practices with insufficient evidence.
What to reconcileConfirm market, exact formulation and the controlling label. The panel practice is not blanket initiation approval; preserve the source-specific lamivudine qualification.
2 source identities and dates
GlobalRPh RX List - KIVEXAGlobalRPh-hosted RX List | Source revision: April 2018
International KIVEXA 600/300 mg fixed-dose source; not a newly verified U.S. product label.
Read this stored source NIH adult abacavir/lamivudine - U.S.-focused comparatorNIH ClinicalInfo HIV Guidelines | Source revision: Source revision date not established in selected retrieval.
Adult U.S.-focused ABC/3TC fixed-combination guidance used to compare an international KIVEXA source; not proof of KIVEXA U.S. approval.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.2.
Source scope / renal recommendation differencesNew v7.4
Tymlos - product and source limitations
Assess tolerance and calcium-related adverse effects. No dialysis schedule is established here.
What to reconcileApply only to the stated formulation, indication and renal population.
2 source identities and dates
Tymlos - labeled renal guidanceDailyMed / product prescribing information | Source revision: DailyMed SPL version 19, posted Aug 17, 2026
Abaloparatide (Tymlos), subcutaneous injection
Read this stored source Tymlos - selected RX renal passageGlobalRPh RX List / product-label mirror | Source revision: Mirror revision not established in the reviewed passage.
Abaloparatide (Tymlos), subcutaneous injection
Read this stored source Selected renal passages reviewed; independent clinician adjudication pending. Added: v7.4.
renal marker and toxicity
Creatinine transport is not a blanket explanation for kidney injury
An isolated creatinine increase can reflect tubular transport, but diarrhea and dehydration can cause true injury. Severe-renal and dialysis exposure remain unknown.
What to reconcileUse the clinical course and appropriate alternative renal markers; do not assume that every rise is benign.
2 source identities and dates
GlobalRPh RX List - VERZENIOGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
VERZENIO oral tablets; product-specific breast-cancer indications and companion therapies. This renal summary does not choose an oncology regimen.
Read this stored source DailyMed / VERZENIO exact product labelDailyMed / Eli Lilly and Company | Source revision: 7/2026
VERZENIO oral tablets; product-specific breast-cancer indications and companion therapies. This renal summary does not choose an oncology regimen.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.5.
formulation
A study dose is not this formulation's prescribing dose
The RX renal section cites a study using another abiraterone product.
What to reconcileDo not import the other product's study dose as the YONSA regimen.
1 source identities and dates
GlobalRPh RX List - YonsaGlobalRPh-hosted RX List | Source revision: Revision date not established in selected retrieval.
YONSA formulation. The cited dialysis study used another abiraterone product.
Read this stored source Source difference identified; final patient-specific adjudication required. Added: vearlier.
multiple adjustment scope
Keep renal, genotype, interaction and study-entry criteria separate
The new mirror summary retains the MDRD table and the distinct trial CrCl exclusion; current official confirmation was not obtained.
What to reconcileDo not compound separate reduction rules or treat a trial-entry exclusion as an approved renal cutoff.
1 source identities and dates
GlobalRPh RX List - CIBINQOGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
CIBINQO abrocitinib, preserving the existing adult record; no age-eligibility expansion is inferred from this renal-only recheck.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.9.
boundary and source conflict
Exact CrCl 30: the contraindication must not be hidden
The original GlobalRPh section prints a below-30 contraindication. The RX mirror explicitly includes 30 in its contraindication while also printing 30-50 in the reduced-dose band.
What to reconcileDo not use the overlapping band as permission at exactly 30. Keep the explicit contraindication visible and obtain current product-specific adjudication.
2 source identities and dates
GlobalRPh RX List - CAMPRALGlobalRPh-hosted RX List | Source revision: 8/2014
CAMPRAL 333 mg delayed-release oral tablets for maintenance of alcohol abstinence with psychosocial support; not treatment of acute withdrawal.
Read this stored source Preserved original GlobalRPh materialGlobalRPh | Source revision: Not established
Historical original source; not revalidated by this note.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.5.
qualitative restriction
A qualitative contraindication is still actionable information
Marked kidney dysfunction is a contraindication in this source, but no numeric cutoff is defined. Dialyzability is discussed in overdose management.
What to reconcileDo not invent a cutoff, borrow another formulation's instructions or turn overdose information into routine dialysis dosing.
1 source identities and dates
GlobalRPh RX List - acetazolamide tabletsGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Acetazolamide oral tablets in the selected historical product mirror; not injection or an extended-release product.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.5.
restriction and incomplete schedule
Two renal exclusion measures and an incomplete further reduction
The source uses both serum-creatinine and CrCl restrictions. It does not supply a complete stepwise regimen as renal function worsens.
What to reconcileKeep both exclusion measures and blood-count precautions. Do not infer the next dose or dialysis supplement.
1 source identities and dates
GlobalRPh RX List - LITHOSTATGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
LITHOSTAT oral adjunct for chronic urea-splitting urinary infection. Source eligibility exclusions, including suitability for definitive treatment, remain essential.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.5.
Source scope / renal recommendation differencesNew v7.4
Tudorza Pressair - product and source limitations
Verify the inhaler, active ingredients and indication. The renal guidance does not supply dialysis timing.
What to reconcileApply only to the stated formulation, indication and renal population.
2 source identities and dates
Tudorza Pressair - labeled renal guidanceDailyMed / product prescribing information | Source revision: DailyMed SPL version 2, posted Dec 08, 2023
Aclidinium bromide (Tudorza Pressair), inhaled powder
Read this stored source Tudorza Pressair - selected RX renal passageGlobalRPh RX List / product-label mirror | Source revision: Mirror revision not established in the reviewed passage.
Aclidinium bromide (Tudorza Pressair), inhaled powder
Read this stored source Selected renal passages reviewed; independent clinician adjudication pending. Added: v7.4.
biomarker and evidence limit
An observed biomarker change is not an unrestricted renal regimen
The source describes an early reversible biomarker pattern and a broad PK statement, without a numerical dialysis dosing schedule.
What to reconcileAssess progressive renal changes; do not import another drug's transport mechanism or a universal acceptable creatinine change.
2 source identities and dates
GlobalRPh RX List - ATTRUBYGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
ATTRUBY oral tablets for transthyretin amyloid cardiomyopathy. The selected finding is a biomarker/PK qualification, not a dialysis dosing protocol.
Read this stored source DailyMed / ATTRUBY exact product labelDailyMed / BridgeBio Pharma, Inc. | Source revision: 6/2026
ATTRUBY oral tablets for transthyretin amyloid cardiomyopathy. The selected finding is a biomarker/PK qualification, not a dialysis dosing protocol.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.5.
professional protocol difference
Severe impairment: label evidence gap versus eviQ full-dose guidance
The label mirror cannot recommend a dose below CrCl 30. The metastatic breast eviQ protocol permits full dose in severe indexed-eGFR bands, including below 15 without KRT. This is both an evidence-position difference and a renal-measure difference.
What to reconcileReconcile oncology indication, treatment intent, renal measure and KRT with oncology/nephrology. Do not describe eviQ as filling the label gap through proven independent trials.
2 source identities and dates
GlobalRPh RX List - KADCYLAGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Intravenous ado-trastuzumab emtansine; not trastuzumab or trastuzumab deruxtecan.
Read this stored source eviQ metastatic breast trastuzumab emtansine - kidney guidanceeviQ / Cancer Institute NSW | Source revision: Source revision date not established in selected retrieval.
Australian metastatic breast cancer protocol; institutional/consensus-derived perspective, not a U.S. label replacement.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.2.
renal measure and toxicity
Indexed MDRD eGFR and diarrhea management are separate decisions
The starting-dose band uses indexed MDRD eGFR; new diarrhea-related renal injury follows the separate toxicity pathway.
What to reconcileConfirm the source measure and reassess toxicity even after selecting the appropriate baseline renal dose.
2 source identities and dates
GlobalRPh RX List - GILOTRIFGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
GILOTRIF tablets for its defined NSCLC indications. Baseline renal dosing and treatment-emergent toxicity modifications are distinct.
Read this stored source DailyMed / GILOTRIF exact product labelDailyMed / Boehringer Ingelheim Pharmaceuticals, Inc. | Source revision: 4/2022
GILOTRIF tablets for its defined NSCLC indications. Baseline renal dosing and treatment-emergent toxicity modifications are distinct.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.5.
baseline versus toxicity
No baseline adjustment does not cancel renal-toxicity stopping rules
A studied baseline CrCl range does not remove the separate Grade 3 interruption and Grade 4 discontinuation instructions.
What to reconcileAssess severity and recovery before resuming; do not dismiss renal injury as a harmless creatinine effect.
1 source identities and dates
GlobalRPh RX List - ALECENSAGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
ALECENSA oral capsules for its ALK-positive NSCLC indications; selected baseline-renal and treatment-toxicity findings.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.5.
Source scope / renal recommendation differences
Binosto - product and source limitations
Use the effervescent preparation instructions. Check the product sodium content for patients with sodium restriction.
What to reconcileApply only to the stated formulation, indication and renal population.
2 source identities and dates
Binosto - labeled renal guidanceDailyMed / product prescribing information | Source revision: DailyMed SPL version 6, effective 2026-02-06; posted Feb 16, 2026
Alendronate (Binosto), effervescent tablet for oral solution
Read this stored source Binosto - selected RX renal passageGlobalRPh RX List / product-label mirror | Source revision: Mirror revision not established in the reviewed passage.
Alendronate (Binosto), effervescent tablet for oral solution
Read this stored source Selected renal passages reviewed; independent clinician adjudication pending. Added: v7.3.
